Hiroaki Oizumi1, Kenji Suzuki2, Takamitsu Banno1, Takeshi Matsunaga1, Shiaki Oh1, Kazuya Takamochi1. 1. Department of General Thoracic Surgery, Juntendo University School of Medicine, 1-3, Hongo 3 Chome, Bunkyo-ku, Tokyo, 113-8431, Japan. 2. Department of General Thoracic Surgery, Juntendo University School of Medicine, 1-3, Hongo 3 Chome, Bunkyo-ku, Tokyo, 113-8431, Japan. kjsuzuki@juntendo.ac.jp.
Abstract
PURPOSES: Resection and reconstruction of the superior vena cava (SVC) is used for the complete resection of advanced lung cancer and mediastinal tumors. However, the optimal postoperative management for this procedure remains to be elucidated. METHODS: 1897 patients with lung cancer and/or mediastinal tumors underwent surgical resection at our institute. Among them, 12 patients underwent combined resection and replacement with a vascular graft of the SVC. Preoperative SVC syndrome was noted in 4, and preoperative chemo and/or radiotherapy were used in 2. The SVC pathway was reconstructed bilaterally in 9 patients (75 %), while 2 patients underwent a right-side single bypass, and 1 had a Y-shaped bypass. Antithrombotic agents were not used postoperatively. The factors related to occlusion of the graft were investigated. The median follow-up time for the surviving patients was 474 days. RESULTS: There were no instances of surgical mortality. Among the 22 grafts, three (14 %) were occluded. One (8 %) case of occlusion was noted on the right side and 2 (20 %) in the left graft. Bilateral reconstruction was performed in all except 2. Two single side reconstructions did not result in occlusion, while 3 occlusions were noted in the patients who had undergone bilateral reconstruction. CONCLUSION: Resection and reconstruction of the SVC system was feasible. Postoperative anti-thrombotic agents are not always needed to prevent acute graft occlusion.
PURPOSES: Resection and reconstruction of the superior vena cava (SVC) is used for the complete resection of advanced lung cancer and mediastinal tumors. However, the optimal postoperative management for this procedure remains to be elucidated. METHODS: 1897 patients with lung cancer and/or mediastinal tumors underwent surgical resection at our institute. Among them, 12 patients underwent combined resection and replacement with a vascular graft of the SVC. Preoperative SVC syndrome was noted in 4, and preoperative chemo and/or radiotherapy were used in 2. The SVC pathway was reconstructed bilaterally in 9 patients (75 %), while 2 patients underwent a right-side single bypass, and 1 had a Y-shaped bypass. Antithrombotic agents were not used postoperatively. The factors related to occlusion of the graft were investigated. The median follow-up time for the surviving patients was 474 days. RESULTS: There were no instances of surgical mortality. Among the 22 grafts, three (14 %) were occluded. One (8 %) case of occlusion was noted on the right side and 2 (20 %) in the left graft. Bilateral reconstruction was performed in all except 2. Two single side reconstructions did not result in occlusion, while 3 occlusions were noted in the patients who had undergone bilateral reconstruction. CONCLUSION: Resection and reconstruction of the SVC system was feasible. Postoperative anti-thrombotic agents are not always needed to prevent acute graft occlusion.
Entities:
Keywords:
Local recurrence; Lung cancer; Thrombosis
Authors: Jean Picquet; Vincent Blin; Corinne Dussaussoy; Yann Jousset; Xavier Papon; Bernard Enon Journal: Surgery Date: 2008-09-19 Impact factor: 3.982
Authors: Michael Lanuti; Pierre E De Delva; Henning A Gaissert; Cameron D Wright; John C Wain; James S Allan; Dean M Donahue; Douglas J Mathisen Journal: Ann Thorac Surg Date: 2009-08 Impact factor: 4.330
Authors: P G Dartevelle; A R Chapelier; U Pastorino; P Corbi; B Lenot; J Cerrina; E A Bavoux; J M Verley; J Y Neveux Journal: J Thorac Cardiovasc Surg Date: 1991-08 Impact factor: 5.209
Authors: Yaron Shargall; Marc de Perrot; Shaf Keshavjee; Gail Darling; Robert Ginsberg; Michael Johnston; Andrew Pierre; Thomas K Waddell Journal: Lung Cancer Date: 2004-09 Impact factor: 5.705